Exabis Library
Welcome to the e-CCO Library!
P417: Long-term deep remission after adalimumab discontinuation in Crohn’s disease patients.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P417: Non-invasive assessment of liver fibrosis by transient elastography and AST to ALT ratio in patients with Crohn's disease treated with methotrexate
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P417: Seroconversion after COVID-19 Vaccination in Inflammatory Bowel Disease Patients
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P417: Ulcerative colitis: let’s talk about extent
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P418 Filgotinib decreases molecular markers of JAK1 signal transduction in Crohn’s disease: concordance with endoscopy and histopathology
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P418: Development and validation of a digital health platform (IBD NutriCare) for telenutrition in patients with Inflammatory bowel disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P418: Does capsule endoscopy impact clinical management in established Crohn’s Disease?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P418: Dose escalation of oral 5-aminosalicylic acid for ulcerative colitis with Mayo endoscopic subscore of one improves long-term prognosis: a one-year multicentre, open-label, randomized controlled trial.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P418: Pharmacodynamic biomarkers demonstrate dose-dependent pharmacological activity of the IL-22Fc fusion protein UTR1147A in healthy volunteers in a phase 1a clinical trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P418: Predictive factors of surgery in the course of Crohn’s disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P418: Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P418: Ulcerative colitis and end-stage liver disease in children with primary sclerosing cholangitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P419 Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn’s disease patients: results from the EVOLVE study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P419: Concentrations of anti-TNF agents in non-inflamed intestinal tissue are associated with the long-term outcome of patients with Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P419: Efficacy of vedolizumab in patients with inflammatory bowel disease and failure of anti-TNF-antibodies
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P419: Frequency of inadequate response to anti-tumour necrosis factor therapy in patients with ulcerative colitis. Preliminary results from POLIBD study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P419: Long-term outcome of ulcerative colitis in pediatric patients who achieved mucosal and histological healing: a real-life referral center experience
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P419: Outcomes at one year after sequential use of high-dose tofacitinib following infliximab in Acute Severe Ulcerative Colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P419: Outcomes for patients with severe acute ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P419: Psychological acceptability of surgery in patients with ulcerative colitis after total colectomy
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM